FIGS. 1A-D




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7



H&E
CD3
CD4
CD8

FIG. 8



A Group
Follow Response,
Survival
Safety
Inject DNX-2401 into
recurrent tumor
Resect tumor
Inject second dose of
DNX-2401 into tumor
resection bed
B Group
Analyze tumor

FIG. 9




FIG. 10

Response	Criteria
Complete Response (CR)	No measurable disease for 4 weeks No corticosteroids Stable or improved clinically
Partial Response (PR)	≥ 50% decrease in sum of products of perpendicular diameters for 4 weeks Stable or reduced corticosteroids Stable or improved clinically
Stable Disease (SD)	Not CR or PR or Progression
Progression	≥ 25% increase, any new lesion, or clinical deterioration